Discovery of (5S,6S,9R)-5-aqmino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro- 5H-cyclohepta[b]pyridin-9-yl4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxylate (BMS-927711): An oral Calcitonin Gene-Related Peptide (CGRP) antagonist in cinical trials for treating migraine

Journal of Medicinal Chemistry

Volumn 55, Issue 23, 2012, Pages 10644-10651

  Luo, Guanglin ^a   Chen, Ling ^a   Conway, Charles M ^a   Denton, Rex ^a   Keavy, Deborah ^a   Signor, Laura ^a   Kostich, Walter ^a   Lentz, Kimberley A ^a   Santone, Kenneth S ^a   Schartman, Richard ^a   Browning, Marc ^a   Tong, Gary ^a   Houston, John G ^a   Dubowchik, Gene M ^a   MacOr, John E ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 6 (2,3 DIFLUOROPHENYL) 6,7,8,9 TETRAHYDRO 5H CYCLOHEPTA[B]PYRIDIN 9 YL 4 (2 OXO 2,3 DIHYDRO 1H IMIDAZO[4,5 B]PYRIDIN 1 YL)PIPERIDINE 1 CARBOXYLATE; ANTIMIGRAINE AGENT; BMS 927711; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CARBOXYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BLOOD FLOW; CALLITRICHINAE; CONTROLLED STUDY; DIASTEREOISOMER; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG SYNTHESIS; EXPERIMENTAL MODEL; HUMAN; MIGRAINE; NONHUMAN; RAT; STEREOCHEMISTRY;

ADMINISTRATION, ORAL; CALCITONIN GENE-RELATED PEPTIDE; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MIGRAINE DISORDERS; PIPERIDINES; PYRIDINES;

EID: 84870996301     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3013147     Document Type: Article

References (23)

1. Hu, X. H.; Markson, L. E.; Lipton, R. B.; Stewart., W. F.; Berger, M. L. Burden of Migraine in the United States: Disability and Economic Costs Arch. Intern. Med. 1999, 159, 813-818
2. Graham, J. P.; Wolff, H. G. Mechanism of migraine headache and the action of ergotamine tartrate Arch. Neurol. Psychiatry 1938, 39, 737-763
3. Olesen, J.; Burstein, R.; Ashina, M.; Tfelt-Hansen, P. Origin of pain in migraine: evidence for peripheral sensitisation Lancet Neurol. 2009, 8, 679-690
4. Goadsby, P. J; Charbit, A. R.; Andreou, A. P; Akerman, S; Holland, P. R. Neurobiology of migraine Neuroscience 2009, 161, 327-341
5. van Rossum, D.; Hanisch, U. K.; Quirion, R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors Neurosci. Biobehav. Rev. 1997, 21, 649-678
6. Goadsby, P. J. Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches Drugs 2005, 65, 2557-2567
7. Edvinsson, L. Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache Cephalalgia 2004, 24, 611-622
8. Williamson, D. J.; Hargreaves, R. J. Neurogenic inflammation in the context of migraine Microsc. Res. Tech. 2001, 53, 167-178
9. Recober, A.; Russo, A. F. Calcitonin gene-related peptide: an update on the biology Curr. Opin. Neurol. 2009, 22, 241-246
10. Olesen, J.; Diener, H. C.; Husstedt, I. W.; Goadsby, P. J.; Hall, D.; Meier, U.; Pollentier, S.; Lesko, L. M. Calcitonin gene related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine N. Engl. J. Med. 2004, 350, 1104-1110
11. Paone, D. V.; Shaw, A. W.; Nguyen, D. N.; Burgey, C. S.; Deng, J. Z.; Kane, S. A.; Koblan, K. S.; Salvatore, C. A.; Mosser, S. D.; Johnston, V. K.; Wong, B. K.; Miller-Stein, C. M.; Hershey, J. C.; Graham, S. L.; Vacca, J. P.; Williams, T. M. Potent, Orally Bioavailable Calcitonin Gene-Related Peptide Receptor Antagonists for the Treatment of Migraine: Discovery of N -[(3 R,6 S)-6-(2,3-Difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo- 2,3-dihydro-1 H -imidazo[4,5- b ]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974) J. Med. Chem. 2007, 50, 5564-5567
12. Hewitt, D. J.; Martin, V.; Lipton, R. B.; Brandes, J.; Ceesay, P.; Gottwald, R.; Schaefer, E.; Lines, C.; Ho, T. W. Randomized Controlled Study of Telcagepant Plus Ibuprofen or Acetaminophen in Migraine Headache 2011, 51, 533-543
13. Tfelt-Hansen, P. Excellent Tolerability but Relatively Low Initial Clinical Efficacy of Telcagepant in Migraine Headache Headache 2011, 51, 118-123
14. Merck recently discontinued the development of telcagepant.
15. Bell, I. M.; Gallicchio, S. N.; Wood, M. R.; Quigley, A. G.; Craig, A.; Stump, C. A.; C. Blair Zartman, C. B.; Fay, J. F.; Li, C.-C.; Lynch, J. J.; Moore, E. L.; Mosser, S. D.; Prueksaritanont, T.; Regan, C. P.; Roller, S.; Salvatore, C. A.; Kane, S. A.; Vacca, J. P.; Selnick, H. G. Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist ACS Med. Chem. Lett. 2010, 1, 24-29
16. Diener, H.-C; Barbanti, P.; Dahlöf, C.; Reuter, U.; Habeck, J.; Podhorna, J. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study Cephalalgia 2011, 31, 573-584
17. Luo, G.; Chen, L.; Conway, C. M.; Keavy, D.; Denton, R.; Kostich, W.; Mercer, S.; Schartman, R.; Signor, L.; Lentz, K.; Browning, M.; Macor, J. E.; Dubowchik, G. M. Discovery of BMS-846372, a Potent and Orally Active Human CGRP Receptor Antagonist for the Treatment of Migraine ACS Med. Chem. Lett. 2012, 3, 337-341
18. Luo, G.; Conway, C. M.; Everlof, G.; Lentz, K. A.; Schartman, R.; Macor, J. E.; Dubowchik, G. M. Unpublished results.
19. Leahy, D. K.; Fan, Y.; Desai, L. V.; Chan, C.; Zhu, J.; Luo, G.; Chen, L.; Hanson, R. L.; Sugiyama, M.; Rosner, T.; Cuniere, N.; Guo, Z.; Gao, Q. Efficient and Scalable Enantioselective Synthesis of a CGRP antagonist Org. Lett. 2012, 14, 4938-4941
20. Luo, G.; Chen, L.; Civiello, R.; Pin, S. S.; Xu, C.; Kostich, W.; Kelley, M.; Conway, C. M.; Macor, J. E.; Dubowchik, G. M. Calcitonin Gene-related Peptide (CGRP) Receptor Antagonists: Pyridine as a Replacement for a Core Amide Group Bioorg. Med. Chem. Lett. 2012, 22, 2917-2921
21. The relative stereochemistry of 17 and 13 were not rigorously established. The absolute stereochemistry of 8 was established through extensive X-ray analysis of 8 and intermediate 23: Qi, G. Unpublished results.
22. i of 0.0921 ± 1.5 nM (n = 2). For the description of all biologic assays, see also: Degnan, A. P.; Chaturvedula, P. V.; Conway, C. M.; Cook, D.; Davis, C. D.; Denton, R.; Han, X.; Macci, R.; Mathias, N. R.; Moench, P.; Pin, S. S.; Ren, S. X.; Schartman, R.; Signor, L.; Thalody, G.; Widmann, K. A.; Xu, C.; Macor, J. E.; Dubowchik, G. M. Discovery of (R)-4-(8-Fluoro-2-oxo-1,2-dihydroquinazolin-3(4 H)-yl)- N -(3-(7-methyl-1 H -indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin- 1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694153): A Potent Antagonist of the Human Calcitonin Gene-Related Peptide Receptor for Migraine with Rapid and Efficient Intranasal Exposure J. Med. Chem. 2008, 51, 4858-4861
23. Conway, C. M.; Dubowchik, G. M.; Cook, D. A.; Signor, L. J.; Thalody, G.; Kostich, W. A.; Gulianello, M.; Huang, Y.; Denton, R.; Lentz, K. A.; Schartman, R.; Johnson, B. M.; Browning, M.; Luo, G.; Chen, L.; Macor, J. E. Unpublished results.